Latest Commercial Sales News

Lithium Universe (ASX: LU7) has acquired exclusive global rights to a University of Edinburgh hydrometallurgical process that extracts gold and copper from electronic waste using recyclable organic compounds, positioning the company at the forefront of sustainable precious metals recovery.

XReality Group (ASX:XRG) posts strong FY26 revenue and ARR growth, marking key milestones with its first commercial MR-1 mixed reality sale to the US Department of Defense and debut European contract with the Swedish Armed Forces.

Wide Open Agriculture has agreed with Curtin University to replace its tiered royalty structure with a single 3.5% flat royalty on net sales, streamlining financial planning and enhancing commercial scalability for its lupin protein technology.

Aguia Resources has addressed all regulatory queries for its Tres Estradas phosphate mine operating licence, with final approval expected soon. The project remains on track for mid-May operational readiness, while its Pampafos fertiliser offers a significant cost edge amid supply shortages in Southern Brazil.

Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.

xReality Group delivered a standout Q3 FY26 with a 62% jump in cash receipts and a new Mixed Reality sale to the US Department of Defense, underpinning its growing Operator XR platform.

Syrah Resources delivered a record 24kt graphite production at Balama and secured US$72 million in equity to support medium-term ramp-up and Vidalia commercialisation, navigating a complex US trade environment.

EVE Health Group has begun commercial sales of Libbo, an oral dissolving film for erectile dysfunction, supported by a new digital men’s health platform. The company also expanded its pharmaceutical pipeline and secured $1.3 million in fresh capital to fund ongoing development and commercialization.

LTR Pharma has wrapped up recruitment for its SPONTAN Phase II pharmacokinetic study, with interim results expected soon to bolster FDA approval efforts. Meanwhile, US commercial talks for ROXUS advance cautiously under the FDA 503(a) personalised medicine pathway.

Volt Group’s first quarter of FY26 saw ordinary revenue receipts surge 150% year-on-year to $3 million, driven by the integration of 4D Delta and strong contributions from its subsidiaries Wescone and EcoQuip.

Green360 Technologies has produced its first commercial batch of Eco-Clay under a tolling deal with Calix, advancing its low-carbon cement alternative towards market entry in Victoria by mid-2026.